OCUL — OCULAR THERAPEUTIX, INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1393434 ·
Last close
$8.17
Market Cap
$1.79B
52W High
$10.94
52W Low
$7.86
ADV30
2,556,602
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 10,785,000 | 9,456,000 | -93,340,000 | -88,612,000 | 732,529,000 | 666,699,000 | 150,955,000 |
| Dec 2025 | 13,250,000 | 11,656,000 | -69,760,000 | -64,654,000 | 808,057,000 | 737,060,000 | 153,747,000 |
| Sep 2025 | 14,544,000 | 12,770,000 | -68,698,000 | -69,418,000 | 410,882,000 | 344,772,000 | 152,653,000 |
| Jun 2025 | 13,459,000 | 11,515,000 | -67,641,000 | -67,814,000 | 451,333,000 | 391,134,000 | 145,417,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-204,883,000
Investing CF
$-11,880,000
Financing CF
$561,721,000
CapEx
$-12,010,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.44
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,157,023,000
Inventory
$3,564,000
Receivables
$30,650,000
ST Investments
—
EBIT TTM
$-254,105,000
Pretax Income TTM
$-265,939,000
Interest Exp TTM
$11,834,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$52,038,000
EBITDA
$-294,815,008
Free Cash Flow
$-148,761,504
Enterprise Value
$1,267,357,184
Total Cash
$666,699,008
Total Debt
$79,462,000
Shares Out
218,960,358
Trailing EPS
$-1.44
Book Value
$2.66
ROE
-68.6%
ROA
-32.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 51,951,000 | -270,017,000 | -265,939,000 | 808,057,000 | 153,747,000 | — | -204,883,000 |
| Dec 2024 | 63,723,000 | -171,781,000 | -193,506,000 | 457,935,000 | 142,591,000 | — | -134,677,000 |
| Dec 2023 | 58,443,000 | -82,382,000 | -80,736,000 | 252,060,000 | 160,929,000 | — | -70,234,000 |
| Dec 2022 | 51,494,000 | -78,654,000 | -71,038,000 | 149,289,000 | 113,910,000 | — | -59,603,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.48
Max Pain — expiry 2026-09-18
max pain strike: $9.00 · spot: $8.17 · call oi: 4,765 · put oi: 2,496
Expected Move to 2026-09-18:
±$2.23
(27.23%) —
implied range
$5.95 –
$10.40
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AGIO | AGIOS PHARMACEUTICALS, INC. | $1.79B | $30.02 | — |
| DMRA | Damora Therapeutics, Inc. | $1.78B | $28.99 | — |
| GENB | Generate Biomedicines, Inc. | $1.79B | $14.00 | — |
| BCAX | Bicara Therapeutics Inc. | $1.78B | $27.10 | — |
| STOK | Stoke Therapeutics, Inc. | $1.80B | $28.86 | — |
News headlines (Yahoo Finance, 1h cache)
3 Russell 2000 Stocks That Concern Us
2026-07-31 18:43 · Yahoo
Pharmaceuticals Stocks Q1 In Review: Ocular Therapeutix (NASDAQ:OCUL) Vs Peers
2026-07-29 01:49 · Yahoo
Is Ocular Therapeutix (OCUL) Still Undervalued Or Is AXPAXLI Hope Already Priced In?
2026-07-24 01:10 · Yahoo
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
2026-07-23 00:02 · Yahoo
3 Cash-Burning Stocks with Open Questions
2026-07-21 10:54 · Yahoo
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-09 20:05 · Yahoo
3 Small-Cap Stocks with Open Questions
2026-07-08 09:06 · Yahoo
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
2026-07-01 11:00 · Yahoo
Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli?
2026-06-25 12:40 · Yahoo
Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings?
2026-06-24 11:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.